| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H29N3O5 |
| Molecular Weight | 367.44 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)[C@@H](O)CNC(C)(C)C
InChI
InChIKey=ANZXOIAKUNOVQU-HNNXBMFYSA-N
InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3/t15-/m0/s1
| Molecular Formula | C18H29N3O5 |
| Molecular Weight | 367.44 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
(R)-Bambuterol is a selective β2-adrenoceptor agonist. R-Bambuterol Hydrochloride Tablets ("Laevo-Bambuterol") is categorized as a Class 1 new drug. Its preclinical studies show that it is more effective and have lower toxicity than Bambuterol, a popular asthma drug currenTLy on the market. Laevo-Bambuterol was approved by the China Food and Drug Administration for the treatment of asthma.
Originator
Approval Year
Sourcing
PubMed
Patents
|
|
RACEMATE -> ENANTIOMER | |||
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 2 of 2 entries